Abstract
Development of institutional guidelines for use of high-cost biotechnology drugs, such as antithrombin III, is a valuable tool in formulary management. This article describes the process by which the University of California Davis Medical Center used an ad hoc committee to the P and T Committee to develop guidelines for antithrombin III use. Performing an objective analysis of available literature to address the appropriate role of a biotechnology agent is necessary to develop consensus guidelines. Approval of use guidelines by the P and T Committee provides the necessary structure for optimal use of biotechnology agents, such as antithrombin III.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 520-531 |
| Number of pages | 12 |
| Journal | Formulary |
| Volume | 30 |
| Issue number | 9 |
| State | Published - 1995 |
Fingerprint
ASJC Scopus subject areas
- Pharmaceutical Science
Cite this
Developing guidelines for biotechnology drug use : Experience with antithrombin III. / Romac, D. R.; Poole, P.; Owings, John T; Mahackian, K.; Foulke, G.; Tharratt, R. S.; Albertson, Timothy E.
In: Formulary, Vol. 30, No. 9, 1995, p. 520-531.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Developing guidelines for biotechnology drug use
T2 - Experience with antithrombin III
AU - Romac, D. R.
AU - Poole, P.
AU - Owings, John T
AU - Mahackian, K.
AU - Foulke, G.
AU - Tharratt, R. S.
AU - Albertson, Timothy E
PY - 1995
Y1 - 1995
N2 - Development of institutional guidelines for use of high-cost biotechnology drugs, such as antithrombin III, is a valuable tool in formulary management. This article describes the process by which the University of California Davis Medical Center used an ad hoc committee to the P and T Committee to develop guidelines for antithrombin III use. Performing an objective analysis of available literature to address the appropriate role of a biotechnology agent is necessary to develop consensus guidelines. Approval of use guidelines by the P and T Committee provides the necessary structure for optimal use of biotechnology agents, such as antithrombin III.
AB - Development of institutional guidelines for use of high-cost biotechnology drugs, such as antithrombin III, is a valuable tool in formulary management. This article describes the process by which the University of California Davis Medical Center used an ad hoc committee to the P and T Committee to develop guidelines for antithrombin III use. Performing an objective analysis of available literature to address the appropriate role of a biotechnology agent is necessary to develop consensus guidelines. Approval of use guidelines by the P and T Committee provides the necessary structure for optimal use of biotechnology agents, such as antithrombin III.
UR - http://www.scopus.com/inward/record.url?scp=0029147149&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029147149&partnerID=8YFLogxK
M3 - Article
C2 - 10151737
AN - SCOPUS:0029147149
VL - 30
SP - 520
EP - 531
JO - Formulary
JF - Formulary
SN - 1082-801X
IS - 9
ER -